Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans.
An LC-MS method was developed for benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP), constituents of "party pills" or "legal herbal highs," and their metabolites in human blood plasma. Compounds were resolved using a mixture of ammonium formate (pH 4.5, 0.01 M) and acetonitrile (flow rate of 1.0 mL/min) with a C18 column. Calibration curves were linear from 1 to 50 ng/mL (R(2) > 0.99); the lower limit of quantification (LLOQ) was 5 ng/mL; the accuracy was >90%; the intra- and interday relative standard deviations (R.S.D) were <5% and <10%, respectively. Human plasma concentrations of TFMPP were measured in blood samples taken from healthy adults (n = 6) over 24 h following a 60-mg oral dose of TFMPP: these peaked at 24.10 ng/mL (±1.8 ng/mL) (C(max) ) after 90 min (T(max)). Plasma concentrations of 1-(3-trifluoromethyl-4-hydroxyphenyl) piperazine peaked at 20.2 ng/mL (±4.6 ng/mL) after 90 min. TFMPP had two disposition phases (t(½) = 2.04 h (±0.19 h) and 5.95 h (±1.63 h). Apparent clearance (Cl/F) was 384 L/h (±45 L/h).
Antia
Ushtana
U
School of Pharmacy, University of Auckland, Auckland, New Zealand. u.antia@auckland.ac.nz
Tingle
Malcolm D
MD
Russell
Bruce R
BR
D000293:Adolescent; D000328:Adult; D002853:Chromatography, Liquid; D005260:Female; D053593:Forensic Toxicology; D006801:Humans; D013287:Illicit Drugs / Q000097:blood* / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D013058:Mass Spectrometry; D000077489:Piperazine; D010879:Piperazines / Q000097:blood* / Q000493:pharmacokinetics* / Q000652:urine; D013048:Specimen Handling; D055815:Young Adult
D013287:Illicit Drugs; D010879:Piperazines; D000077489:Piperazine; C018406:1-(3-trifluoromethylphenyl)piperazine; C006737:1-benzylpiperazine